HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ipsilateral breast tumor relapse after breast conserving surgery in women with breast cancer.

Abstract
Ipsilateral breast tumor relapse (IBTR) is a potentially a significant problem after breast conserving surgery (BCS). With a median follow-up period of 64.7 months, IBTR occurred as a first relapse in 67 (3.0%) of a total of 2243 patients and distant recurrence occurred in 167 (7.4%). A positive surgical margin and the omission of radiotherapy (RT) were independently associated with IBTR. The five-year cumulative IBTR rates were 5.1% in patients with positive margins and 2.0% in the patients with negative margins. The five-year cumulative IBTR rates were 1.8% in patients with RT and 8.1% in patients without RT. IBTR was independently associated with distant-recurrence-free survival rates as well as age, nodal metastasis, lymphovascular invasion and progesterone receptor status. The five-year distant-recurrence-free survival rates were 81.9% in patients with IBTR and 93.2% in patients without IBTR. In order to prevent IBTR, a negative margin and the administration of RT are therefore considered to be important in patients who undergo BCS.
AuthorsTakashi Yoshida, Hiroyuki Takei, Masafumi Kurosumi, Jun Ninomiya, Yuko Ishikawa, Yuji Hayashi, Katsunori Tozuka, Hanako Oba, Kenichi Inoue, Toshio Tabei
JournalBreast (Edinburgh, Scotland) (Breast) Vol. 18 Issue 4 Pg. 238-43 (Aug 2009) ISSN: 1532-3080 [Electronic] Netherlands
PMID19625190 (Publication Type: Journal Article)
Topics
  • Adult
  • Breast Neoplasms (mortality, pathology, radiotherapy, surgery)
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphatic Metastasis
  • Mastectomy, Segmental
  • Multivariate Analysis
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local (epidemiology)
  • Radiotherapy, Adjuvant
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: